enGene Therapeutics Inc. Share Price
NASDAQ: ENGNenGene Therapeutics Inc. Stock Performance
Open $1.81 | Prev. Close $1.79 | Circuit Range N/A |
Day Range $1.79 - $1.83 | Year Range $1.41 - $12.25 | Volume 39,123 |
Average Traded $1.81 |
enGene Therapeutics Inc. Share Price Today
As of 10 August 2026, enGene Therapeutics Inc.'s share price is $1.79. The stock opened at $1.81, compared to its previous close of $1.79. During today's trading session, enGene Therapeutics Inc.'s share price traded between $1.79 and $1.83, with an average price of $1.81. Over the past 52 weeks, the stock has recorded a high of $12.25 and a low of $1.41. In terms of performance, enGene Therapeutics Inc.'s share price has declined by 82.15% over the last six months and is down 61.09% on a year-on-year basis.
enGene Therapeutics Inc. Share Price Chart
enGene Therapeutics Inc. Quarterly Profit & Loss
All figures in USD
enGene Therapeutics Inc. Annual Profit & Loss
All figures in USD
About enGene Therapeutics Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
enGene Therapeutics Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.76 | $1.79 | +0.00% |
Jul 2026 | $1.74 | $1.79 | +2.29% |
Jun 2026 | $1.81 | $1.75 | -4.89% |
May 2026 | $7.29 | $1.84 | -74.79% |
Apr 2026 | $6.96 | $7.30 | +7.51% |
Mar 2026 | $9.96 | $6.79 | -32.30% |
Feb 2026 | $9.55 | $10.03 | +5.19% |
Jan 2026 | $8.86 | $9.54 | +6.18% |
Dec 2025 | $7.83 | $8.98 | +11.84% |
Nov 2025 | $7.41 | $8.03 | +9.76% |
Oct 2025 | $6.97 | $7.32 | +9.34% |
Sep 2025 | $4.69 | $6.69 | +45.43% |